Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database

Open access

Abstract

BACKGROUND: Androgen excess is a defining feature of polycystic ovary syndrome (PCOS), which affects 10% of women and represents a lifelong metabolic disorder, with increased risk of type 2 diabetes, hypertension, and cardiovascular events. Previous studies have suggested an increased risk of nonalcoholic fatty liver disease (NAFLD) in individuals with PCOS and implicated androgen excess as a potential driver. METHODS AND FINDINGS: We carried out a retrospective longitudinal cohort study utilizing a large primary care database in the United Kingdom, evaluating NAFLD rates in 63,120 women with PCOS and 121,064 age-, body mass index (BMI)-, and location-matched control women registered from January 2000 to May 2016. In 2 independent cohorts, we also determined the rate of NAFLD in women with a measurement of serum testosterone (n = 71,061) and sex hormone-binding globulin (SHBG; n = 49,625). We used multivariate Cox models to estimate the hazard ratio (HR) for NAFLD and found that women with PCOS had an increased rate of NAFLD (HR = 2.23, 95% CI 1.86-2.66, p < 0.001), also after adjusting for BMI or dysglycemia. Serum testosterone >3.0 nmol/L was associated with an increase in NAFLD (HR = 2.30, 95% CI 1.16-4.53, p = 0.017 for 3-3.49 nmol/L and HR = 2.40, 95% CI 1.24-4.66, p = 0.009 for >3.5 nmol/L). Mirroring this finding, SHBG <30 nmol/L was associated with increased NAFLD hazard (HR = 4.75, 95% CI 2.44-9.25, p < 0.001 for 20-29.99 nmol/L and HR = 4.98, 95% CI 2.45-10.11, p < 0.001 for <20 nmol/L). Limitations of this study include its retrospective nature, absence of detailed information on criteria used to diagnosis PCOS and NAFLD, and absence of data on laboratory assays used to measure serum androgens. CONCLUSIONS: We found that women with PCOS have an increased rate of NAFLD. In addition to increased BMI and dysglycemia, androgen excess contributes to the development of NAFLD in women with PCOS. In women with PCOS-related androgen excess, systematic NAFLD screening should be considered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1002542

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Selection of patients with polycystic ovary syndrome (PCOS) and controls. A total of 694 general practices were eligible for inclusion in the study, with a total of 2,706,062 women for the study period 2000–2016. A total of 64,787 women were listed as having PCOS according to the criteria defined in the “Methods” section. Controls were randomly matched to women with PCOS at a ratio of 2:1 within each practice, generating a random control cohort of 123,928 women. Participants with a documented history of alcohol excess were excluded; therefore, the final cohort consisted of 63,120 women with PCOS and 121,064 controls.
Fig 1 Selection of patients with polycystic ovary syndrome (PCOS) and controls. A total of 694 general practices were eligible for inclusion in the study, with a total of 2,706,062 women for the study period 2000–2016. A total of 64,787 women were listed as having PCOS according to the criteria defined in the “Methods” section. Controls were randomly matched to women with PCOS at a ratio of 2:1 within each practice, generating a random control cohort of 123,928 women. Participants with a documented history of alcohol excess were excluded; therefore, the final cohort consisted of 63,120 women with PCOS and 121,064 controls.CC BY · PubMed Central
Fig 2 Impact of BMI and polycystic ovary syndrome (PCOS) on the hazard of nonalcoholic fatty liver disease (NAFLD). PCOS and control groups were subcategorized into lean, overweight, and obese groups according to BMI, with lean control women designated as the reference category (unexposed, BMI <25 kg/m2). The analysis is adjusted for age, Townsend score of social deprivation, diabetes or impaired glucose regulation, and hypothyroidism at baseline. The hazard of NAFLD increased with BMI in both control women and women with PCOS. Lean women with PCOS had an almost 2-fold higher hazard of NAFLD compared to lean controls. The highest hazard of developing NAFLD was observed in the obese PCOS cohort.
Fig 2 Impact of BMI and polycystic ovary syndrome (PCOS) on the hazard of nonalcoholic fatty liver disease (NAFLD). PCOS and control groups were subcategorized into lean, overweight, and obese groups according to BMI, with lean control women designated as the reference category (unexposed, BMI <25 kg/m2). The analysis is adjusted for age, Townsend score of social deprivation, diabetes or impaired glucose regulation, and hypothyroidism at baseline. The hazard of NAFLD increased with BMI in both control women and women with PCOS. Lean women with PCOS had an almost 2-fold higher hazard of NAFLD compared to lean controls. The highest hazard of developing NAFLD was observed in the obese PCOS cohort.CC BY · PubMed Central
Fig 3 Hazard of nonalcoholic fatty liver disease (NAFLD) according to serum testosterone and sex hormone-binding globulin (SHBG) levels. (A) Serum testosterone (nmol/L) was available in 71,061 unselected women. Using women with testosterone levels below 1.0 nmol/L as a reference cohort, the hazard of NAFLD was 2.4-fold higher in those with serum testosterone levels of >3 nmol/l. (B) Serum SHBG was available in 49,625 unselected women. Using a reference cohort with SHBG levels of ≥60 nmol/L, the hazard of NAFLD was almost 5-fold elevated in patients with serum levels of <30 nmol/L. Both analyses are adjusted for age, Townsend score, diabetes or impaired glucose regulation, and hypothyroidism at baseline.
Fig 3 Hazard of nonalcoholic fatty liver disease (NAFLD) according to serum testosterone and sex hormone-binding globulin (SHBG) levels. (A) Serum testosterone (nmol/L) was available in 71,061 unselected women. Using women with testosterone levels below 1.0 nmol/L as a reference cohort, the hazard of NAFLD was 2.4-fold higher in those with serum testosterone levels of >3 nmol/l. (B) Serum SHBG was available in 49,625 unselected women. Using a reference cohort with SHBG levels of ≥60 nmol/L, the hazard of NAFLD was almost 5-fold elevated in patients with serum levels of <30 nmol/L. Both analyses are adjusted for age, Townsend score, diabetes or impaired glucose regulation, and hypothyroidism at baseline.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 208

Metadata

Authors
Kumarendran, B., O’Reilly, M. W., Manolopoulos, K. N., Toulis, K. A., Gokhale, K. M., Sitch, A. J., Wijeyaratne, C. N., Coomarasamy, A., Arlt, W., & Nirantharakumar, K.
Affiliations
  • University of Kelaniya (LK)
  • University of Birmingham (GB)
  • University of Colombo (LK)
Corresponding author
  • Arlt, Wiebke
  • Nirantharakumar, Krishnarajah
Venue
PLOS Medicine
Published
2018-03-28
Volume
15
Issue
3
Pages
e1002542
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2794855941
Cited by
206
References
59
Citations by year
2026: 20 · 2025: 27 · 2024: 20 · 2023: 20 · 2022: 37 · 2021: 34 · 2020: 23 · 2019: 19 · 2018: 5
FWCI
21.60
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
Wellcome Trust (099909, 092283)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
polycystic ovary syndrome, hyperandrogenism, non-alcoholic fatty liver disease, women, serum testosterone, sex hormone-binding globulin, NAFLD risk, primary care, metabolic disorders, dysglycemia, body mass index, type 2 diabetes, cardiovascular risk, hypertension, insulin resistance, dyslipidemia, polycystic ovary morphology
MeSH terms
Adolescent, Adult, Androgens, Diabetes Mellitus, Type 2, Female, United Kingdom, Humans, Insulin Resistance, Longitudinal Studies, Male, Middle Aged, Polycystic Ovary Syndrome, Retrospective Studies, Risk Factors, Body Mass Index, Prevalence, Multivariate Analysis, Proportional Hazards Models, Young Adult, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. https://app.cochat.ai/papers/10.1371/journal.pmed.1002542
The paper
Kumarendran, B., O’Reilly, M. W., Manolopoulos, K. N., Toulis, K. A., Gokhale, K. M., Sitch, A. J., Wijeyaratne, C. N., Coomarasamy, A., Arlt, W., & Nirantharakumar, K. (2018). Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1002542

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.